Immunogen (IMGN) 10-Q2022 Q1 Quarterly report

Filed: 6 May 22, 11:46am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: ability, accurate, agency, aid, alkylate, arrangement, attributed, azacytidine, blood, broad, camptothecin, cease, chemistry, chemotherapy, chief, China, choice, CMC, Code, collectively, companion, compendia, conflict, constrained, diagnostic, distinct, DNA, Eastern, efficacy, Eli, eligible, ensuing, Ergomed, experimentation, extensive, factor, fail, fallopian, February, feedback, final, flat, fully, GLORIOSA, goal, Gynecologic, halt, harm, hold, Hong, human, inability, incidence, inconclusive, independent, insufficient, Kong, launch, legal, lengthy, Lilly, Macau, maintenance, medium, MIRV, necessitate, nonclinical, November, ORR, outcome, parallel, pending, People, peritoneal, Pivekimab, PLC, predominantly, prevent, PrimeVigilance, promised, promising, proximity, PVEK, rare, realized, Redmile, reliance, reprioritization, Republic, resolved, revert, Russia, safe, scope, served, SGO, show, side, sponsored, stage, sublicensable, successfully, sunirine, Taiwan, tax, TCJA, therapeutic, tiered, triplet, tube, turn, Ukraine, unacceptable, uncertain, understanding, undue, USA, vitro, vivo, women, worldwide

Removed: Academy, actively, acute, add, adjustment, Administration, alpha, amendment, announce, approximating, ASU, azacitidine, blastic, charge, commencing, confirmatory, consisted, currency, CytomX, decision, demonstrating, dendritic, Euro, folate, Food, fourth, free, fulfill, furniture, impairment, initially, intended, leasehold, lesser, leukemia, located, longer, month, moved, myeloid, neoplasm, obligated, overexpressed, PDM, periodic, plasmacytoid, record, recoverable, Reform, rentable, restructuring, retention, scored, seek, sharing, simplify, Simplifying, survival, tail, Topic, unrecognized, unsecured, vacate, Virtual

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated IMGN transcripts

IMGN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of ImmunoGen, Inc., a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report for the period ended March 31, 2022 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 6, 2022	/s/ MARK J. ENYEDY
	Mark J. Enyedy
	President, Chief Executive Officer
	(Principal Executive Officer)

Dated: May 6, 2022	/s/ SUSAN ALTSCHULLER Ph.D.
	Susan Altschuller Ph.D.
	Senior Vice President, Chief Financial Officer
	(Principal Financial Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.